Telomerase and breast cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Current therapies for breast cancer include treatments that are toxic and often result in drug resistance. Telomerase, a cellular reverse transcriptase that maintains the ends of chromosomes (telomeres), is activated in the vast majority of breast cancers (over 90% of breast carcinomas) but not in normal adjacent tissues. Telomerase is thus an attractive target for both diagnosis and therapy because of its distinct pattern of expression. We address the use of telomerase in the diagnostics of breast pathology, as well as the use of telomerase inhibitors in the treatment and prevention of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 1×
“Although other mechanisms to maintain telomere stability are possible, the mechanism for lengthening telomeres in humans is almost always by the reactivation or upregulation of telomerase [4].”
BackgroundThe DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
A survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · cited 7×
“Although preliminary data showed 88% of all stages of breast carcinoma having positive TRAP [9], closer investigation and careful handling of initially negative samples revealed the value may be closer to 95% [10].”
BackgroundMethodInfluentialSelf-citationThe RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227
Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80538-3 · Cited by 1,784
The two-stage mechanism controlling cellular senescence and immortalization
Wright, W. E., & Shay, J. W. (1992) · Experimental Gerontology · doi:10.1016/0531-5565(92)90069-c · Cited by 383
Self-citation
Cited by
Telomeres in cancer: tumour suppression and genome instability
Maciejowski, J., & de Lange, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.171 · Cited by 745
The causes and consequences of polyploidy in normal development and cancer
Davoli, T., & de Lange, T. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154234 · Cited by 424
In situ analyses of genome instability in breast cancer
Chin, K., de Solorzano, C. O., Knowles, D., Jones, A., Chou, W., Rodriguez, E. G., Kuo, W.-L., Ljung, B.-M., Chew, K., Myambo, K., et al. (2004) · Nature Genetics · doi:10.1038/ng1409 · Cited by 361
“and reactivation of telomerase occurs during transition from UDH to DCI”
BackgroundTelomerase: A target for cancer therapeutics
Shay, J. W., & Wright, W. E. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00159-9 · Cited by 339
Self-citationTelomere-related Genome Instability in Cancer
DE LANGE, T. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.032 · Cited by 182
Telomere fusions in early human breast carcinoma
Tanaka, H., Abe, S., Huda, N., Tu, L., Beam, M. J., Grimes, B., & Gilley, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120062109 · Cited by 52
“Our finding that telomere fusions appear in DCIS correlates with previous reports of telomere shortening, telomerase activation, and other genomic aberrations detected in DCIS (10, 11, 17, 18).”
Background
Metadata
- Authors
- Herbert, B.-S., Wright, W. E., & Shay, J. W.
- Venue
- Breast Cancer Research
- Published
- 2001-06
- Volume
- 3
- Issue
- 3
- Pages
- 146-9
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1912008246
- Cited by
- 88
- References
- 6
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.